| Sep 14 |
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
|
| Sep 14 |
Incyte Zynyz improves progression-free survival in anal cancer
|
| Sep 6 |
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
|
| Aug 30 |
Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?
|
| Aug 29 |
Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
|
| Aug 27 |
Exploring Three High Growth Tech Stocks In The United States
|
| Aug 21 |
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
|
| Aug 19 |
Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
|
| Aug 16 |
Armed with Phase III win, Incyte eyes label expansion for Monjuvi
|
| Aug 15 |
Incyte's Monjuvi meets primary endpoint in follicular lymphoma phase 3 trial
|
